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BACKGROUND
Patients with diabetes are at higher risk for death and cardiovascular outcomes than 
the general population. We investigated whether the excess risk of death and cardio-
vascular events among patients with type 2 diabetes could be reduced or eliminated.
METHODS
In a cohort study, we included 271,174 patients with type 2 diabetes who were reg-
istered in the Swedish National Diabetes Register and matched them with 1,355,870 
controls on the basis of age, sex, and county. We assessed patients with diabetes 
according to age categories and according to the presence of five risk factors (ele-
vated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, 
albuminuria, smoking, and elevated blood pressure). Cox regression was used to 
study the excess risk of outcomes (death, acute myocardial infarction, stroke, and 
hospitalization for heart failure) associated with smoking and the number of vari-
ables outside target ranges. We also examined the relationship between various 
risk factors and cardiovascular outcomes.
RESULTS
The median follow-up among all the study participants was 5.7 years, during which 
175,345 deaths occurred. Among patients with type 2 diabetes, the excess risk of 
outcomes decreased stepwise for each risk-factor variable within the target range. 
Among patients with diabetes who had all five variables within target ranges, the 
hazard ratio for death from any cause, as compared with controls, was 1.06 (95% 
confidence interval [CI], 1.00 to 1.12), the hazard ratio for acute myocardial in-
farction was 0.84 (95% CI, 0.75 to 0.93), and the hazard ratio for stroke was 0.95 
(95% CI, 0.84 to 1.07). The risk of hospitalization for heart failure was consistently 
higher among patients with diabetes than among controls (hazard ratio, 1.45; 95% CI, 
1.34 to 1.57). In patients with type 2 diabetes, a glycated hemoglobin level outside 
the target range was the strongest predictor of stroke and acute myocardial infarction; 
smoking was the strongest predictor of death.
CONCLUSIONS
Patients with type 2 diabetes who had five risk-factor variables within the target 
ranges appeared to have little or no excess risk of death, myocardial infarction, or 
stroke, as compared with the general population. (Funded by the Swedish Associa-
tion of Local Authorities and Regions and others.)
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Type 2 diabetes is a complex disease that leads to continuous medical care with comprehensive, multifactorial strategies for 
reducing cardiovascular risk. Patients with type 
2 diabetes have risks of death and cardiovascular 
events that are 2 to 4 times as great as the risks 
in the general population.1 Results from random-
ized trials support a range of interventions that 
target isolated risk factors such as elevated levels 
of glycated hemoglobin, blood pressure, and cho-
lesterol to prevent or postpone complications of 
type 2 diabetes. The Steno-2 Study investigated 
the effects of multifactorial risk-factor control by 
means of behavior modification and pharmaco-
logic therapy and showed long-lasting reductions 
in the risks of death and cardiovascular events 
among patients in whom these risks were reduced, 
as compared with patients who had been ran-
domly assigned to usual care.2,3
The extent to which the excess risk associated 
with type 2 diabetes may be mitigated, or poten-
tially eliminated, by contemporary evidence-based 
treatment and multifactorial risk-factor modifica-
tion is unclear. In a nationwide cohort, we evalu-
ated the association between the excess risks of 
death and cardiovascular outcomes among pa-
tients with type 2 diabetes, according to the num-
ber of risk-factor variables within therapeutic 
guideline levels, as compared with controls who 
were matched for age, sex, and county in Sweden. 
Risk-factor data were not available for controls.
In ancillary analyses, we estimated the 
strength of the associations between various risk 
factors and the incremental risks of death and 
cardiovascular outcomes associated with diabe-
tes. Moreover, we examined the association be-
tween selected risk-factor variables such as levels 
of glycated hemoglobin, systolic blood pres-
sure, and low-density lipoprotein (LDL) choles-
terol within evidence-based target ranges and 
these outcomes.
Me thods
Study Design and Support
The Regional Ethics Review Board of Gothen-
burg, Sweden, approved the study. All the patients 
provided written informed consent before inclu-
sion in the Swedish National Diabetes Register. 
The Swedish Association of Local Authorities and 
Regions and other nonprofit agencies supported 
the study; no industry support was provided.
Data Sources and Study Cohort
The Swedish National Diabetes Register has been 
described previously.1,4 Type 2 diabetes was de-
fined according to epidemiologic criteria — treat-
ment with diet, with or without the use of oral 
antihyperglycemic agents, or treatment with in-
sulin, with or without the use of oral antihyper-
glycemic agents. The latter category (insulin use) 
applied only to patients who were 40 years of age 
or older at the time of diagnosis. Patients with at 
least one entry in the register between January 1, 
1998, and December 31, 2012, were included in 
the study. At baseline (defined as the first entry 
in the register), each patient with type 2 diabetes 
was matched for age, sex, and county with five 
controls without diabetes who were randomly 
selected from the Swedish population register by 
Statistics Sweden.
We constructed two cohorts of patients with 
type 2 diabetes. One cohort excluded patients 
with previous stroke, acute myocardial infarction, 
or amputation; those who had undergone dialy-
sis or renal transplantation; and those with a 
body-mass index (the weight in kilograms divided 
by the square of the height in meters) of less than 
18.5. The second cohort of patients with type 2 
diabetes had exclusion criteria that were similar 
to those of the first cohort but also excluded pa-
tients with previous coronary heart disease, atrial 
fibrillation, or heart failure. Controls who met 
any of these criteria were excluded without the 
exclusion of their matched patient.
Outcomes
We assessed death from any cause, fatal or non-
fatal acute myocardial infarction (henceforth re-
ferred to as acute myocardial infarction), fatal or 
nonfatal stroke (henceforth referred to as stroke), 
and hospitalization for heart failure. Outcomes 
were identified in hospital discharge records with 
use of codes in the International Classification of 
Diseases, 9th Revision and 10th Revision. The specific 
codes are listed in Table S1 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org. Patients were followed until an 
event occurred or until December 31, 2013, for all 
the outcomes except for death from any cause, for 
which follow-up ended on December 31, 2014.
Statistical Analysis
Crude incidence rates were calculated according 
to the number of risk-factor variables within tar-
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get ranges and are presented as events per 10,000 
patient-years of observation with exact Poisson 
confidence intervals of 95%. We constructed Cox 
regression models and included baseline values in 
the models. All the models were adjusted for so-
cioeconomic variables (income, marital status, 
immigrant status, and educational level), with 
stratification according to sex to allow for dif-
ferent underlying baseline hazards among men 
and women, and age was used as the time scale. 
Some models were adjusted for preexisting con-
ditions. For death from any cause, we adjusted 
for coronary heart disease and heart failure; for 
myocardial infarction, we adjusted for atrial fi-
brillation and heart failure; for stroke, we adjust-
ed for atrial fibrillation, heart failure, and coro-
nary heart disease; and for hospitalization for 
heart failure, we adjusted for atrial fibrillation 
and coronary heart disease.
For the main analyses, we estimated the risk 
of each outcome among patients with type 2 
diabetes, according to the number of risk-factor 
variables within target ranges, as compared with 
the controls matched for age, sex, and county. We 
defined whether the risk-factor variables were 
within target ranges on the basis of guideline-
recommended target levels.5,6 The regression mod-
els included the covariable “category,” which de-
noted the number of risk-factor variables that were 
not within the target range (scale, none to five 
variables). The following five risk factors were 
considered: the glycated hemoglobin level (cutoff 
value, ≥7.0% or ≥53 mmol per mole), systolic and 
diastolic blood pressure (cutoff value, ≥140 mm Hg 
for systolic blood pressure or ≥80 for diastolic 
blood pressure), albuminuria (the presence of 
microalbuminuria or macroalbuminuria), smok-
ing (being a current smoker at study entry), and 
the LDL cholesterol level (cutoff value, ≥2.5 mmol 
per liter [97 mg per deciliter]).
We constructed a separate Cox model for each 
age category, according to age at baseline: young-
er than 55 years of age, 55 years to younger than 
65 years of age, 65 years to younger than 80 years 
of age, and 80 years of age or older. We adjusted 
for the duration of diabetes by assigning matched 
controls a duration of 0 years, and patients with 
type 2 diabetes had their duration of diabetes 
centralized around the grand mean (the mean 
duration among all the study participants).
Among patients with type 2 diabetes, we ana-
lyzed the relative importance of the risk factors. 
Relative importance provides an estimate of how 
important each risk factor is in terms of predict-
ing the outcome. Several methods are available 
for this task; we chose to calculate the relative 
importance as measured by the R2 values of the 
models,7 and we tested the consistency of the re-
sults by calculating the explainable log-likelihood 
that was attributable to each risk factor.
We assessed the level associated with the low-
est risk, given the glycated hemoglobin level, 
systolic blood pressure, and LDL cholesterol level, 
by modeling the association between each risk 
factor and the outcomes using restricted cubic 
splines. The evidence-based target level was set 
as the reference for each risk factor; not smok-
ing was set as the reference for smoking status.
Missing data were imputed with the multi-
variate imputation by chained equations (MICE) 
algorithm. We imputed five complete data sets; 
a list of the variables that were used in the im-
putation model is provided in Table S3 in the 
Supplementary Appendix. The estimates from each 
imputed data set were combined into one overall 
estimate with the use of Rubin’s rule. Figures S4 
and S5 in the Supplementary Appendix show the 
frequency of missing-data elements and the dis-
tribution of each variable before and after the 
imputation. For the main analysis, we pooled the 
results across all five imputed data sets; the re-
sults of the analyses with the imputed data sets 
were virtually identical to those in the cohort with 
complete cases and were thus consistent with a 
complete-case analysis. For the ancillary analyses, 
we used the first imputed data set. All the analy-
ses were performed with the use of RStudio soft-
ware, version 3.2.3.
R esult s
Study Population
A total of 433,619 patients with type 2 diabetes and 
2,168,095 controls were identified, and 271,174 
patients with type 2 diabetes and 1,355,870 
matched controls were included in the study 
(Fig. S1 in the Supplementary Appendix). The 
median follow-up among all the study partici-
pants was 5.7 years, during which 175,345 deaths 
occurred. The baseline characteristics of the pa-
tients with complete data on all five risk factors 
(96,673 patients with diabetes [35.6%]) and their 
matched controls are presented in Table 1. The 
number of patients in each risk-factor group in 
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the imputed data sets is also shown in Table 1. 
The complete data regarding the characteristics 
of the participants at baseline are presented in 
Table S4 in the Supplementary Appendix.
The mean age of the patients was 60.60 years, 
and 47,777 of 96,673 patients (49.4%) were wom-
en. Table S5 in the Supplementary Appendix shows 
the baseline characteristics of the patients for 
whom data were missing for at least one risk fac-
tor. Figure S6 in the Supplementary Appendix 
shows the trends in risk factors over the period 
from 1998 through 2012, and Figure S7 in the 
Supplementary Appendix shows how causes of 
death varied among the groups according to the 
number of risk-factor variables in the target 
ranges.
Risk of Cardiovascular Events
A total of 37,825 patients with diabetes (13.9%) 
and 137,520 controls (10.1%) died during the 
study period. The numbers of events, incidence 
rates, and hazard ratios for all the outcomes 
among patients with diabetes, as compared with 
controls, at increasing numbers of risk-factor vari-
ables, as well as the risks of death among men and 
women, are presented in Table S2 in the Supple-
mentary Appendix.
Figure 1 shows the adjusted hazard ratios for 
the outcomes, according to age category and the 
number of risk-factor variables within target rang-
es, among patients with diabetes as compared 
with matched controls. The results show a step-
wise increase in the hazard ratios for each ad-
ditional variable that was not within the target 
range among patients with diabetes, and the incre-
mental risks of cardiovascular events and death 
that were associated with diabetes decreased in 
a stepwise fashion from younger to older age 
groups. Patients with diabetes who were 80 years 
of age or older at baseline had the lowest incre-
mental risk of cardiovascular events and death, 
as compared with controls. In the overall cohort, 
patients with type 2 diabetes who had no risk-
factor variables outside the target ranges had a 
marginally higher risk of death than the controls 
(hazard ratio, 1.06; 95% confidence interval [CI], 
1.00 to 1.12).
Patients with diabetes who were 80 years of 
age or older at baseline and had no risk factors 
outside target ranges had the lowest hazard ratio, 
as compared with controls, for acute myocardial 
infarction across all the groups (hazard ratio, 
0.72; 95% CI, 0.49 to 1.07) (Fig. 1B). Overall, 
patients with type 2 diabetes who had no risk-
factor variables outside the target ranges had a 
lower risk of acute myocardial infarction than 
the matched controls (hazard ratio, 0.84; 95% CI, 
0.75 to 0.93). Corresponding estimates for the 
excess risk of stroke are shown in Figure 1C. The 
overall hazard ratio for stroke among patients 
with no risk-factor variables outside the target 
ranges, as compared with controls, was 0.95 
(95% CI, 0.84 to 1.07) (Table S2 in the Supple-
mentary Appendix). Similar to the findings with 
acute myocardial infarction, there was a higher 
incremental risk of stroke in the younger age 
categories and for each variable that was not 
within the target range. Estimates regarding hos-
pitalization for heart failure are shown in Fig-
ure 1D. Patients with type 2 diabetes who were 
younger than 55 years of age and had all five 
risk-factor variables outside the target ranges 
had the highest excess risk of hospitalization for 
heart failure of all the outcomes assessed (haz-
ard ratio vs. control, 11.35; 95% CI, 7.16 to 18.01). 
The overall hazard ratio for hospitalization for 
heart failure among patients with no risk-factor 
variables outside the target ranges, as compared 
with controls, was 1.45 (95% CI, 1.34 to 1.57) 
(Table S2 in the Supplementary Appendix).
Risk-Factor Strength and Levels  
in Patients with Type 2 Diabetes
Figure 2A shows the predictors with the apparent 
greatest importance with regard to death from 
any cause. The five strongest predictors regard-
ing the risk of death among patients with type 2 
diabetes were smoking, physical activity, marital 
status, glycated hemoglobin level, and use of 
statins (lipid-lowering medication). The data shown 
in Figure 3A suggest that lower glycated hemo-
globin levels than are currently recommended in 
guidelines were associated with a lower risk of 
death.
The strongest predictors regarding the risk of 
acute myocardial infarction were the glycated 
hemoglobin level, systolic blood pressure, LDL 
cholesterol level, physical activity, and smoking 
(Fig. 2B). These risk factors showed a linear as-
sociation with the risk of acute myocardial in-
farction (Fig. 3B).
The strongest predictors regarding the risk of 
stroke were the glycated hemoglobin level, systolic 
blood pressure, duration of diabetes, physical ac-
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tivity, and atrial fibrillation (Fig. 2C). Levels be-
low the guideline target levels for glycated hemo-
globin and systolic blood pressure were associated 
with lower risks of stroke (Fig. 3C).
Hospitalization for heart failure was predict-
ed primarily by atrial fibrillation and a body-mass 
index outside the target range; a low estimated 
glomerular filtration rate and high glycated he-
moglobin level were also strong predictors of 
this outcome (Fig. 2D). The risk of hospitaliza-
tion for heart failure was marginally lower at 
glycated hemoglobin levels of less than 53 mmol 
per mole (Fig. 3D).
The glycated hemoglobin level was the stron-
gest or the second strongest predictor regarding 
the risk of the outcomes in five of the eight mod-
els (Fig. 2). Smoking was the strongest predictor 
of death.
Relative Risk-Factor Strength and Explained 
Log Likelihood
Figures S2 and S3 in the Supplementary Appen-
dix show the relative strength of the associations 
for predictors of cardiovascular outcomes in pa-
tients with type 2 diabetes, with or without pre-
existing conditions, with the use of explained 
log-likelihood. The results were broadly consis-
tent with the results obtained with the use of 
explained relative risk (R2) models.
Discussion
Our analysis of Swedish nationwide registry data 
from 1998 through 2012 showed that patients 
with type 2 diabetes and five selected risk-factor 
variables within target range had, at most, mar-
ginally higher risks of death, stroke, and myocar-
dial infarction than the general population. The 
study indicates that having all five risk-factor vari-
ables within the target ranges could theoretically 
eliminate the excess risk of acute myocardial in-
farction. However, there was a substantial excess 
risk of hospitalization for heart failure among 
patients who had all the variables within target 
ranges. We identified a monotonic relationship 
among younger age, increasing number of vari-
ables not within target ranges, and a higher rela-
tive risk of adverse cardiovascular outcomes. The 
results suggest that there may be greater poten-
tial gains from more aggressive treatment in 
younger patients with diabetes.
The following risk factors were considered to 
be the strongest predictors for cardiovascular out-
comes and death: low physical activity, smoking, 
and glycated hemoglobin, systolic blood-pressure, 
and LDL cholesterol levels outside the target rang-
es. Using real-world data, we found that levels of 
glycated hemoglobin, systolic blood pressure, and 
LDL cholesterol that were lower than target levels 
were associated with lower risks of acute myocar-
dial infarction and stroke.
Randomized trials investigating the effect of 
multifactorial cardiovascular risk-factor interven-
tion in patients with type 2 diabetes are scarce, 
and contemporary studies were designed to mea-
sure the cumulative incidence of cardiovascular 
events among patients with various risk factors 
(e.g., hyperglycemia, hypertension, dyslipidemia, 
and microalbuminuria) who received intensive 
therapy, as compared with those who received 
conventional therapy.2,3,8,9 Observational studies 
and randomized trials have shown inconsistent 
evidence of effects of glycated hemoglobin levels 
below contemporary guideline levels (<7.0%) with 
regard to cardiovascular events and death.10-15
In the present analyses, a glycated hemoglo-
bin level outside the target range was a strong 
predictor for all outcomes, especially for athero-
thrombotic events, which shows the importance 
of dysglycemia with regard to these complications. 
Figure 1 (facing page). Adjusted Hazard Ratios for 
Outcomes, According to Age Category and Number  
of Risk-Factor Variables outside Target Ranges, among 
Patients with Type 2 Diabetes, as Compared with 
Matched Controls.
Hazard ratios show the excess risk of each outcome 
among patients with type 2 diabetes, as compared 
with matched controls from the general population, 
according to age categories and to the number of risk-
factor variables (scale, none to five) that were outside 
target ranges currently recommended in guidelines. 
The analysis included patients with type 2 diabetes 
and controls matched for age, sex, and county in Swe-
den. We constructed a Cox hazards model for each 
age category, and these models were adjusted for the 
covariable “category”; this covariable denotes the 
number of risk-factor variables that were within target 
ranges. These Cox model analyses were performed on 
five imputed data sets for each age category, and haz-
ard ratios were pooled from all the data sets with the 
use of Rubin’s rule.
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Figure 2. Relative Importance of Risk Factors for Predicting Death from Any Cause, Acute Myocardial Infarction, Stroke, 
and Hospitalization for Heart Failure among Patients with Type 2 Diabetes, with or without Preexisting Conditions.
The estimated explained relative risk (i.e., relative importance) shows the strength of the association for various 
risk-factor variables (with values outside the target ranges) for predicting death (Panel A), acute myocardial infarc-
tion (Panel B), stroke (Panel C, facing page), and hospitalization for heart failure (Panel D, facing page) among pa-
tients with type 2 diabetes. Results were obtained from the first imputed data set; there were no significant differ-
ences between the sets. The analysis was restricted to patients with type 2 diabetes. We constructed a Cox hazard 
model for each outcome, which included every predictor. We then constructed a separate Cox model for each pre-
dictor and permutated covariables from each of these Cox models to estimate the explained relative risk (R2).  
R2 was generated by developed applications for the Cox model and is bounded between 0 and 1. Risk factors show-
ing a clear and substantial R2 measure, as compared with other adjacent predictors, are considered to be relevant. 
Full definitions of the risk factors and the values that were considered to be outside the target ranges are provided 
in the Supplementary Appendix. The body-mass index is the weight in kilograms divided by the square of the height 
in meters. LDL denotes low-density lipoprotein, and GFR glomerular filtration rate.
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Low physical activity was also a strong predictor 
of cardiovascular outcomes and death, but ran-
domized trials have not shown long-lasting ben-
eficial effects from increased physical activity in 
patients with diabetes.16-18
With regard to hospitalization for heart fail-
ure, the present analyses showed that the pres-
ence of atrial fibrillation, a high body-mass index, 
and a glycated hemoglobin level and renal func-
tion outside the target ranges were the strongest 
predictors. These findings indicate that cardio-
renal mechanisms may contribute to the develop-
ment of heart failure in patients with type 2 dia-
betes. A high body-mass index was a stronger 
risk factor for heart failure than for other out-
comes, which may explain why the risks associated 
with this outcome may continue to be higher 
among patients with type 2 diabetes than among 
controls, since patients with diabetes are, on 
average, heavier than compared controls.
Our study shows, in accordance with previous 
studies, that lower systolic blood pressure is asso-
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ciated with lower risks of cardiovascular outcomes 
and death.19 The Systolic Blood Pressure Interven-
tion Trial (SPRINT) showed that systolic blood-
pressure targets below guideline levels in patients 
without diabetes were associated with a lower risk 
of cardiovascular outcomes and death.20 However, 
the Action to Control Cardiovascular Risk in Dia-
betes (ACCORD) trial examined the same systolic 
blood-pressure targets in patients with type 2 
diabetes (<120 mm Hg vs. <140 mm Hg) and did 
not show a significant effect on cardiovascular 
mortality.15,21 Our analysis implies that systolic 
blood pressure is a central factor for virtually all 
outcomes in patients with diabetes, and lower lev-
els of systolic blood pressure are associated with 
significantly lower risks of acute myocardial in-
farction and stroke among patients with diabetes. 
The assessment of systolic blood pressure and its 
relation to death and heart failure is more diffi-
cult, owing to potential reverse causality. More-
specific trials of blood-pressure reduction to dif-
ferential targets in patients with type 2 diabetes 
may be warranted.20,22
Our observational study has several strengths 
but also some notable limitations. Almost all the 
patients with type 2 diabetes in Sweden were 
included. The epidemiologic definitions of type 
2 diabetes and the outcomes are well validated. 
We did not consider changes in the risk-factor 
variables during follow-up, and although this 
would have some advantages, the approach we 
used minimizes the risk of reverse causation in 
the interpretation of the results. In addition, we 
did not distinguish between patients with all or 
some variables within target range without any 
specific intervention and patients who had been 
medically treated to attain the observed risk-fac-
tor levels. We also acknowledge that residual 
confounding and reverse causation are impossible 
to overcome fully. Finally, given the observational 
nature of this work, this cannot be a complete 
comparison of the effects of treating risk factors; 
rather, because some patients may have had risk-
factor variables in the target ranges without treat-
ment, the findings represent the prognostic im-
portance of such risk factors for persons with 
diabetes.
In conclusion, patients with type 2 diabetes 
who had five risk-factor variables within target 
ranges appeared to have little or no excess risks of 
death, myocardial infarction, and stroke as com-
pared with the general population.
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